Recently, the FDA has increased the age indication for Merck’s human papillomavirus (HPV) 9-valent vaccine – otherwise known as Gardasil 9 – from men from 9-15, to ages 9-26. The vaccine is designed to prevent anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58.

Jacques Cholat, President of Merck Vaccines, states that “This is an important approval that now aligns the indication for Gardasil 9 in males and females ages 9 through 26 to that of Gardasil, and also supports the CDC’s [US Centers for Disease Control and Prevention] HPV vaccine recommendations for use in males.”

 

Find the full article HERE!